Oxford Radcliffe NHS Trust (Cancer & Haematology Centre, Churchill Hospital)
Welcome,         Profile    Billing    Logout  
 7 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Collins, Graham
RADAR, NCT04685616: Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Recruiting
3
1042
Europe, US, RoW
Involved site radiotherapy, Doxorubicin, Bleomycin, Brentuximab vedotin, Vinblastine, Dacarbazine, Haematopoietic growth factor, Filgrastim, G-CSF, Pegfilgrastim
University College, London, Takeda, University of Miami, European Organisation for Research and Treatment of Cancer - EORTC, Australasian Leukaemia and Lymphoma Group, Seagen Inc., Canadian Cancer Trials Group
Hodgkin Lymphoma
09/30
09/32
AVENuE, NCT03617666: Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study

Active, not recruiting
2
49
Europe, RoW
Avelumab, Bavencio
University College, London, Pfizer
Hodgkin Lymphoma
07/22
05/25
ANIMATE, NCT03337919: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma

Active, not recruiting
2
78
Europe
Nivolumab, Opdivo®
University College, London, Bristol-Myers Squibb
Hodgkin Lymphoma
03/23
02/26
SGN35-032, NCT04569032 / 2020-002336-74: A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Active, not recruiting
2
82
Europe, US, RoW
brentuximab vedotin, ADCETRIS, cyclophosphamide, doxorubicin, prednisone
Seagen Inc.
Peripheral T-cell Lymphoma
05/24
12/25
P+R-ICE, NCT05221645: Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2
65
Europe
Pembrolizumab, KEYTRUDA, Rituximab, MabThera, Ifosfamide, Carboplatin, Etoposide
University of Southampton, Merck Sharp & Dohme LLC
Diffuse Large B Cell Lymphoma
10/24
12/25
RATiFY, NCT05627115: Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma

Not yet recruiting
2
80
NA
Tislelizumab, AVD, Radiotherapy, Response-adapted incorporation of tislelizumab
University College, London, BeiGene
Hodgkin Lymphoma
10/28
10/28
NCT05463263: A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

Recruiting
1/2
180
Europe, US
STP938
Step Pharma, SAS
Lymphoma, B-Cell, Lymphoma, T-Cell
12/25
12/25

Download Options